Can beta blockers commonly used for blood pressure and heart rhythm contribute to ovarian cancer treatment and prolong survival?

The American Cancer Society published striking observational findings suggesting that blood pressure and heart rhythm medicines called beta blockers prolong survival in ovarian cancer patients.
In ovarian cancer, among the common cancers in women, new chemotherapy drugs, targeted therapies and immunotherapies, oncology's bright face illuminating the future although not yet actively available to us, have greatly strengthened our options. Today we share a study that could assist these increasingly successful treatments. It suggests beta blockers, widely used in medicine, may benefit ovarian cancer patients. Let us examine what these drugs are.
When arterial hardening or certain diseases occur, the sympathetic nervous system activates and sends signals through hormones such as adrenaline for the heart to work harder. Cardiac beta receptors detect these signals, increasing heart rate. Beta blockers (beloc, vasoxen, dilatrend, dideral, concor, tensinor, etc.), commonly preferred for arterial hardening causing hypertension, arrhythmias or palpitations, block these receptors and prevent frantic cardiac activity. They slow heart rate and make heart muscle contractions more effective.
A recently published American Cancer Society study examined whether prolonged sympathetic activation influences ovarian cancer development and spread. With an average age of 63 (range 21-93), 1425 women participated, of whom 269 used beta blockers for other conditions alongside chemotherapy. Patients taking them for heart and/or blood pressure disorders during chemotherapy had survival of approximately 48 months, compared with an average 42 months in those receiving only cancer treatment. Detailed analysis found substantially longer overall survival with non-heart-specific (nonselective) beta blockers (95 months). These are the most frequently preferred blood pressure and rhythm medicines (such as beloc and dideral). The study suggested that suppressing abnormal, prolonged sympathetic activation could benefit ovarian cancer treatment.
Dear friends, findings from such new research contributing to treatment and prolonging survival in ovarian cancer are encouraging. However, an important point is that drugs affecting the heart and blood vessels particularly should not be taken without medical advice.
Sources
Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.
Cancer. 2015 Aug 24. doi: 10.1002/cncr.29392.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.